Metro, Inc. Just Made the Deal of the Year

The acquisition this week of Jean Coutu by Metro, Inc. (TSX:MRU) has unprecedented potential over the long term for Metro and its investors.

| More on:
The Motley Fool

Metro, Inc. (TSX:MRU) announced this week the takeover of Jean Coutu pharmacy group following a series of negotiations between the two companies in a deal valued at $4.5 billion.

Jean Coutu has over 400 pharmacy locations in Quebec, Ontario, and New Brunswick, whereas Metro has operations in over 850 locations scattered across Quebec and Ontario. Together, the combined company will be Quebec’s single largest employer in the private sector with over 86,000 employees.

What does this deal mean for Metro?

Consumer trends are constantly changing, and a shift in recent years has pushed those tastes to include a greater demand for health-related products that are commonly found in pharmacies.

This deal for Metro is akin to a similarly poised move that Loblaw Companies Ltd. did a few years back to acquire Shoppers Drug Mart. That deal was a likely catalyst for this deal, but it’s not the only one that Metro has conducted recently.

Over the past decade, Metro has completed several acquisitions that have greatly expanded the company’s reach and footprint, such as the acquisition of A&P Canada, buying into Alimentation Couche Tard Inc. and, more recently, Marché Adonis.

Metro is already forecasting $75 million in synergies over the next three years, with shared warehousing, a greatly expanded and unified online presence, and cross-merchandising.

Cross-merchandising could be a massive opportunity for Metro over time, as Metro products placed in Jean Coutu locations could draw in the shoppers that are looking for those few items that aren’t worth going over to Metro for. This was a strategy deployed by Loblaw after the Shoppers transition was wildly successful.

While the deal is still subject to regulatory and shareholder approval, the combined company will account for an impressive $16 billion in annual revenue and free cash flow of $500 million.

Shareholders of Jean Coutu will be voting on the proposal at a special meeting being scheduled for November.

Metro has indicated that the company will sell assets to help finance the deal, expressing a desire to maintain the company’ current credit rating. Part of that asset sale could mean a sale of part or all of Metro’s 32.2 million shares of Alimentation Couche Tard. Those shares alone could fetch upwards of $1.8 billion at current prices.

Is Metro a good investment?

Even without this deal, Metro is a compelling investment opportunity. The company has registered moderate gains in 2017, and the stock has averaged a little over 8% growth annually over the past two years.

Metro’s dividend, which amounts to $0.16 per quarter for a yield of 1.53%, is likely not going to be the first choice for income-seeking investors, but the income is both welcome and stable. Metro has steadily raised that dividend over the past few years, and there’s little reason to think that practice won’t continue going forward.

Perhaps some of the most intriguing reasons to consider Metro in advance of the current deal comes in the form of Coutu’s operations. Few investors realize that Coutu is not only a pharmacy reseller, but it also manufacturers some generic medications. This could provide an advantage over the competition as well as a new source of revenue for Metro.

Coutu is also a large land owner. The company collects rent and a myriad of fees from the 184 buildings the company owns in Quebec, which are franchisee owned.

In my opinion, Metro remains an intriguing investment opportunity for those investors with an eye towards long-term growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Axentiou has no position in any stocks mentioned. Alimentation Couche Tard is a recommendation of Stock Advisor Canada.

More on Investing

ETF stands for Exchange Traded Fund
Dividend Stocks

How to Earn $2,000 in Passive Income in 2025 With Less Than $51,000 in Savings

You can invest in Canadian high yield stocks via the Vanguard FTSE Canadian High Yield Dividend ETF (TSX:VDY).

Read more »

Asset Management
Investing

Where Will Restaurant Brands International Stock Be in 1/3/5 Years?

Let's dive into where Restaurant Brands (TSX:QSR) could be headed over the near to medium term, shall we?

Read more »

profit rises over time
Tech Stocks

4 Reasons to Buy Constellation Software Stock Like There’s No Tomorrow

Constellation Software stock continued its climb upwards after recent earnings, and this only adds to its appeal.

Read more »

Trans Alaska Pipeline with Autumn Colors
Energy Stocks

Is Enbridge Stock a Good Buy?

Enbridge provides a 6.5% dividend yield right now.

Read more »

calculate and analyze stock
Bank Stocks

Is National Bank of Canada Stock a Buy for its 3.3% Dividend Yield?

While National Bank stock might seem to have a lower dividend yield, its upside could offer a valuable way to…

Read more »

An investor uses a tablet
Investing

4 Value Stocks That Are Must Buys for Canadians in November

Whether you want to add growth or defence to your portfolio, these four stocks are some of the best Canadian…

Read more »

Oil industry worker works in oilfield
Energy Stocks

Is Suncor Stock a Buy, Sell, or Hold for 2025?

Suncor stock looks undervalued as the company continues to increases cash flows, earnings, and shareholder returns.

Read more »

monthly desk calendar
Dividend Stocks

This 7.8% Dividend Stock Pays Out Every Month

Not all monthly dividend stocks are created equal. And this top stock is certainly a strong choice for passive income.

Read more »